A method for estimating pharmacokinetic risks of concentration-dependent drug interactions from preclinical data

Drug Metabolism and Disposition

Volumn 27, Issue 12, 1999, Pages 1479-1487

  Ramanathan, Murali ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; KETOCONAZOLE; TERFENADINE;

ANALYTIC METHOD; ARTICLE; DRUG METABOLISM; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS; STOCHASTIC MODEL; VALIDATION PROCESS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; PROBABILITY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STOCHASTIC PROCESSES;

EID: 0032744843     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ball CA and Torous WN (1983) A simplified jump process for common stock returns. J Financ Quant Anal 18:53-65.
2. Beckers S (1981) A note on estimating the parameters of the diffusion-jump model of stock returns. J Financ Quant Anal 16:127-140.
3. Benet LZ, Kroetz DL and Sheiner LB (1996) Pharmacokinetics: The dynamics of drug absorption, distribution and elimination, in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG eds) pp 3-27, McGraw-Hill Book Company, New York.
4. Carrillo JA and Benitez J (1994) Caffeine metabolism in a healthy Spanish population: Nacetylator phenotype and oxidation pathways. Clin Pharmacol Ther 55:293-304.
5. Coutant JE, Westmark PA, Nardella PA, Walter SM and Okerholm RA (1991) Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr 570:139-148.
6. D'Argenio DZ and Schlumitzky A (1992) Users Guide: Adapt II Mathematical Software for Pharmacokinetic/Pharmacodynamic Systems Analysis. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
7. Eichelbaum M and Gross AS (1990) The genetic polymorphism of debrisoquine/sparteinc metabolism - clinical aspects. Pharmacol Ther 46:377-394.
8. Grasela TH Jr, Antal EJ, Ereshefsky L, Wells BG, Evans RL and Smith RB (1987) An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 42:433-441.
9. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbelt K, Counihan M, Tobias S and Shader R1 (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247.
10. Guzy S and Hunt CA (1997) Validation of a decision support system for use in drug development: Pharmacokinetic data. Pharm Res 14:1287-1297.
11. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences [published erratum appears in J Am Med Assoc (1993) 269:2088]. J Am Med Assoc 269:1513-1518.
12. Ito K (1951) On stochastic differential equations. Mem Am Math Soc 4:1-51.
13. Jarrow RA and Rudd A (1983) Option Pricing. Dow Jones-Irwin, Homewood, IL.
14. Lazarou J, Pomeranz BH and Corey PN (1998) Incidence of adverse drug reactions in hospilalized patients: A meta-analysis of prospective studies. J Am Med Assoc 279:1200-1205.
15. Lesar TS, Briceland L and Stein DS (1997) Factors related to errors in medication prescribing. J Am Med Assoc 277:312-317.
16. Levy P (1925) Calcul des Probabilites. Gauthiers-Villars, Paris.
17. Lindeberg JW (1922) Eine neue Herleitung des Exponentialgeselzes des Wahrscheilichkeitreschnung. Math Zeitschrift 15:221.
18. Merton RC (1976) Option pricing when underlying stock returns are discontinuous. J Financ Econ 3:125-144.
19. Merton RC (1990) Continuous-Time Finance. Blackwell Scientific Publications, Cambridge, MA.
20. Okerholm RA, Weiner DL, Hook RH, Walker BJ, Leeson GA, Biedenbach SA, Cawein MJ, Dusebout TD, Wright GJ, Myers M, Schindler V and Cook CE (1981) Bioavailability of terfenadine in man. Biopharm Drug Dispos 2:185-190.
21. Peck CC, Temple R and Collins JM (1993) Understanding consequences of concurrent therapies. J Am Med Assoc 269:1550-1552.
22. Press JS (1967) A compound events model for security prices. J Bus 40:317-335.
23. Rowland M, Sheiner LB and Steimer J-L (1985) Variability in Drug Therapy: Description. Estimation, and Control: A Sandoz Workshop, Raven Press, New York.
24. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS and Shader RI (1994) In vitro prediction of the terfenadine-keloconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227.
25. Woosley RL, Chen Y, Freiman JP and Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc 269:1532-1536.
26. Yun CH, Okerholm RA and Guengerich FP (1993) Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 21:403-409.